Chemomab Therapeutics Ltd (CMMB) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Chemomab Therapeutics Ltd   (NASDAQ: CMMB)


Chemomab Therapeutics Ltd's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Chemomab Therapeutics Ltd's ROI in the fourth quarter of 2025?
Chemomab Therapeutics Ltd achieved a return on average invested assets (ROI) of 31.57 % in its fourth quarter of 2025, which is below Chemomab Therapeutics Ltd's average return on investment, which stands at 66.27%.

ROI fell compared to the third quarter of 2025, despite the net income growth of % from the third quarter of 2025.

Within the Healthcare sector 14 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 43 to 54.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM -9.1 % -13.93 % -17.03 % -31.54 % -39.97 %
Y / Y Net Income Change TTM -43.92 % -48.78 % -48.78 % -65.65 % -73.39 %
Investment (TTM) in Millions 13 12 10 10 14
Return On Investment (TTM) 31.57 % 73.92 % 72.05 % 58.93 % 51.17 %
CMMB's Overall Ranking # 54 # 43 # # #
Seq. Investment Change TTM -1.18 % -2.53 % 0.21 % -5.83 % -6.43 %
Seq. Net Income Change TTM -57.79 % 0 % 22.51 % 8.45 % -61.45 %
Net Income (TTM) in Millions 4 9 9 7 6

CMMB Company Profile >> Back to CMMB Roi Comparisons >> See Annual CMMB Return On Investment



Return On Investment CMMB's Ranking
Within: No.
Industry # 4
Sector # 15
Overall # 54

Return On Investment Statistics
High Average Low
523.21 %
66.27 %
-214.65 %
(Dec 31 2018)   (Jun 30 2020)







Financial Statements
Chemomab Therapeutics Ltd's IV. Quarter Investments $ 13 Millions CMMB's Balance sheet
Chemomab Therapeutics Ltd's IV. Quarter Income $ 9 Millions Quarterly CMMB's Income Statement
CMMB's Income by Division See CMMB's Income by Division


CMMB Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 12 14 17 36 61
Y / Y Investment Growth -8.89 % -20.36 % -53.08 % -41.07 % 456.76 %
Net Income in Millions -9 -14 -24 -28 -12
Y / Y Net Income Growth - - - - -
Annual Return On Investment -72.93 % -103.01 % -142.5 % -76.32 % -20.3 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CMMB's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CMMB's Competitors
Subscribers only: Roi for Chemomab Therapeutics Ltd's Suppliers
Subscribers only: Return On Investment for CMMB's Customers

Other Ratios
CMMB's Roa CMMB's Inventory Turnover Ratio CMMB's Growth Rates CMMB's Dividend Statistics
CMMB's Profitability Ratios CMMB's Asset Turnover Ratio CMMB's Dividend Growth
CMMB's Roe CMMB's Valuation Ratios CMMB's Financial Strength Ratios CMMB's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Advanced Biomed Inc.  84.64 %
Earth Science Tech Inc   78.43 %
Exelixis Inc   71.31 %
Entera Bio Ltd   63.91 %
Tg Therapeutics Inc   63.77 %
Aurinia Pharmaceuticals Inc   56.37 %
Pulmatrix Inc   53.09 %
Novavax inc   51.88 %
Q32 Bio Inc   50.33 %
Idexx Laboratories Inc  48.69 %
Theravance Biopharma inc   46.03 %
Elite Pharmaceuticals Inc   45.80 %
Enlivex Therapeutics Ltd  45.75 %
Gsk Plc  44.94 %
Galmed Pharmaceuticals Ltd   43.72 %
Abeona Therapeutics Inc   42.25 %
Alpha Tau Medical Ltd  42.04 %
Dariohealth Corp   41.31 %
Acadia Pharmaceuticals Inc   39.64 %
Medinotec Inc   37.45 %
Zevra Therapeutics Inc   36.78 %
Oramed Pharmaceuticals Inc  35.86 %
Ptc Therapeutics inc   35.12 %
Mettler toledo International Inc   34.74 %
Newgenivf Group Limited  32.05 %
Eli Lilly And Company  31.62 %
Indivior Pharmaceuticals Inc   31.00 %
Hutchmed china Limited  30.87 %
Medpace Holdings Inc   30.44 %
Adma Biologics Inc   28.75 %

Date modified: 2026-07-07T10:09:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.